These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9435858)

  • 1. Activated neutrophils as effector cells for bispecific antibodies.
    Valerius T; Würflein D; Stockmeyer B; Repp R; Kalden JR; Gramatzki M
    Cancer Immunol Immunother; 1997; 45(3-4):142-5. PubMed ID: 9435858
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.
    Tacken PJ; Hartshorn KL; White MR; van Kooten C; van de Winkel JG; Reid KB; Batenburg JJ
    J Immunol; 2004 Apr; 172(8):4934-40. PubMed ID: 15067073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody.
    Michon J; Moutel S; Barbet J; Romet-Lemonne JL; Deo YM; Fridman WH; Teillaud JL
    Blood; 1995 Aug; 86(3):1124-30. PubMed ID: 7542496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.
    Bakema JE; Ganzevles SH; Fluitsma DM; Schilham MW; Beelen RH; Valerius T; Lohse S; Glennie MJ; Medema JP; van Egmond M
    J Immunol; 2011 Jul; 187(2):726-32. PubMed ID: 21653835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.
    Duval M; Posner MR; Cavacini LA
    J Virol; 2008 May; 82(9):4671-4. PubMed ID: 18272577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
    Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin A: magic bullet or Trojan horse?
    Heineke MH; van Egmond M
    Eur J Clin Invest; 2017 Feb; 47(2):184-192. PubMed ID: 28024097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies targeting cancer cells.
    Peipp M; Valerius T
    Biochem Soc Trans; 2002 Aug; 30(4):507-11. PubMed ID: 12196124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
    Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
    Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
    Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
    Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.